Diagnosis of cancer using tumor-mimetic cell surface antigen from chemically modified normal cells
OwnerMadhao B. Sahasrabudheinventor
Life of this patent
Estimating the term…
Abstract
A tumor-mimetic cell surface antigen (TMCSA) is produced by chemical treatment of normal human cells with fluordinitrobenzene. This TMCSA cross-reacts with tumor antigens from every type of tumor examined of any histopathologic type. Cancer is detected by detecting the presence of lymphocytes sensitized to tumor antigens based on their reactivity with TMCSA in a binding assay or lymphocyte stimulation assay.
Claims25
A method for detecting the presence of a non-leukemia form of cancer in a subject having lymphocytes sensitized to a tumor antigen, which method comprises
- (a) obtaining a sample of blood from said subject;
- and
- (b) assaying in vitro
- (i) reactivity other than antibody secretion, or
- (ii) binding of leucocytes of said sample with a tumor-mimetic cell surface antigen (TMCSA) which TMCSA comprises:
- (1) normal human cells which have been chemically treated with fluorodinitrobenzene, dinitrochlorobenzene or trinitrochlorobenzene to modify the cell membrane such that said chemically treated cells present TMCSA on their surface;
- (2) solubilized membranes of said chemically treated cells;
- or
- (3) affinity purified TMCSA produced from said solubilized membranes using a TMCSA-specific antibody,
- wherein detection of reactivity or binding with said TMCSA indicates the presence of said non-leukemia form of cancer in said subject.
A method for detecting the presence of lymphocytes in a subject which are sensitized to a tumor antigen and are reactive with TMCSA, which method comprises
- (a) obtaining a sample of blood from said subject;
- (b) assaying in vitro
- (i) reactivity other than antibody secretion, or
- (ii) binding of lymphocytes of said sample with a TMCSA which comprises:
- (1) normal human cells which have been chemically treated with fluorodinitrobenzene, dinitrochlorobenzene or trinitrochlorobenzene to modify the cell membrane such that said chemically treated cells present TMCSA on their surface;
- (2) solubilized membranes of said chemically treated cells;
- or
- (3) affinity purified TMCSA produced from said solubilized membranes using a TMCSA-specific antibody,
- wherein detection of reactivity or binding with said TMCSA indicates the presence of said sensitized lymphocytes.
A method for monitoring therapy of a non-leukemia cancer in a patient to detect a therapeutic effect, which method comprises:
- (a) subjecting said patient to a cancer therapy;
- (b) obtaining a sample of blood from said patient at two or more time points before, during or after said therapy,
- (c) assaying in vitro
- (i) reactivity other than antibody secretion, or
- (ii) binding of leucocytes of each of said samples with a TMCSA, which comprises:
- (1) normal human cells which have been chemically treated with fluorodinitrobenzene, dinitrochlorobenzene or trinitrochlorobenzene to modify the cell membrane such that said chemically treated cells present TMCSA on their surface;
- (2) solubilized membranes of said chemically treated cells;
- or
- (3) affinity purified TMCSA produced from said solubilized membranes using a TMCSA-specific antibody,
- wherein a decrease in said reactivity or binding from one time point before, during or after therapy to a subsequent time point during or after therapy is an indication of a therapeutic effect.
A kit for use in an enzyme assay to detect the presence of lymphocytes sensitized to a tumor antigen, said kit being compartmentalized to receive in close confinement therein one or more containers, said kit comprising a first container containing a TMCSA preparation conjugated to an enzyme, which TMCSA comprises
- (a) normal human cells which have been chemically treated with fluorodinitrobenzene, dinitrochlorobenzene or trinitrochlorobenzene to modify the cell membrane such that said chemically treated cells present TMCSA on their surface;
- (b) solubilized membranes of said chemically treated cells;
- or
- (c) affinity purified TMCSA produced from said solubilized membranes using an TMCSA-specific antibody, which preparation binds detectably to lymphocytes sensitized to a tumor antigen.
Dependencies are inferred from the claim text.